Resumen de: WO2023047348A1

The present invention relates to stabilized recombinant pre-fusion SARS CoV-2 S proteins, and fragments thereof, as well as nucleic acids molecules encoding the SARS CoV-2 S proteins or fragments thereof, and to uses thereof.

Resumen de: AU2021341790A1

Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered invariant natural killer T (iNKT) cells for off-the-shelf use for COVID-19 clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and are suitable for allogeneic cellular therapy.

Resumen de: WO2023046680A1

The invention relates to a pharmaceutical dosage form comprising (i) a physiologically acceptable cetylpyridinium salt and (ii) benzydamine or a physiologically acceptable salt thereof for use in the prevention and/or treatment of a coronavirus infection. Preferably, the coronavirus is a severe acute respiratory syndrome-related coronavirus, more preferably a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Resumen de: US2023100072A1

The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.

Resumen de: US2023099592A1

This invention relates to a novel composition and method for RNA/mRNA production as well as amplification using viral RNA replicase and/or RNA-dependent RNA polymerase (RdRp) enzymes and the use of associated RNA/mRNA products thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA/mRNA sequences carrying at least a replicase/RdRp-binding site in the 5′- or 3′-end, or both. The RNA/mRNA so obtained is useful for not only producing mRNA vaccines and/or RNA-based medicines but for generating the mRNA-associated proteins, peptides, and/or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase/RdRp-mediated RNA/mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and/or bacteriophage RNA-dependent RNA polymerases (RdRp) in either modified or non-modified mRNA and/or protein compositions, particularly coronaviral (e.g. COVID-19) and hepatitis C viral (HCV) RdRp enzymes.

Resumen de: US2023102810A1

The present disclosure provides a method for an effective decoction preparation of unripe green Mangifera indica to treat and prevent anti-SARS-CoV-2. The disclosure extends to uses of such preparation as medicaments and to methods of treating anti-SARS-CoV-2 infections, and tolerating the vaccine side-effects. The disclosure further extends to methods for preventing anti-SARS-CoV-2 infections by coating objects and surfaces with the compositions.

Resumen de: US2023100793A1

A rapid-testing mask is worn by a user, and includes a covering portion, a strap portion and a rapid-testing portion. The covering portion is provided to cover the mouth and the nose of the user. The covering portion includes an inner layer close to the user and an outer layer opposite to the user. The strap portion is connected to the covering portion and is worn on the user. The rapid-testing portion is arranged on the inner layer of the covering portion, and receives a gas exhaled from the mouth or the nose of the user to generate an indication signal according to the gas. The indication signal is a rapid-testing result of whether the user is suffering from diseases of pneumonia, influenza and COVID-19 (Coronavirus disease 2019), to monitor health status of the user in real time.

Resumen de: US2023099027A1

The invention relates to virucidal compositions comprising a sialic acid (SA) moiety, pharmaceutical compositions and disinfection and/or sterilization compositions comprising thereof and uses thereof in disinfection and/or sterilization methods and in treating and/or preventing COVID-19 and other respiratory diseases caused by coronaviruses and/or influenza viruses.

Resumen de: WO2023049643A1

Disclosed herein, inter alia, are peptidomimetic or peptide analog compounds for inhibiting SARS-CoV-2, compounds utilized in a method of treating COVID-19, the method comprising administering to a subject in need thereof an effective amount of such a compound, and further disclosed are compounds utilized in a method of inhibiting the binding of SARS-CoV-2 spike protein to the human angiotensin-converting enzyme 2 (ACE-2), the method comprising contacting the SARS-CoV-2 spike protein with such a compound.

Resumen de: WO2023048759A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

Resumen de: WO2023048694A1

An apparatus is provided for delivering IR and/or UV radiation, to an area or a surface in which virions, such as SARS-CoV-2 (the virus that causes the disease, COVID-19), may exist, wherein the IR radiation is intended to degrade the viral envelope of the virions and wherein the UV radiation is intended to break specific molecular bonds in order to degrade the RNA of the virion contained within a viral envelope.

Resumen de: WO2023048656A2

The present disclosure relates to antibodies and antigen-binding fragments that bind specifically to the receptor-binding domain of SARS-CoV-2, compositions thereof, and methods of production. Also provided are methods of use, including methods of SARS-CoV-2 detection, methods for treating or preventing SARS-CoV-2 infections and associated symptoms.

Resumen de: WO2023048532A1

The present invention relates to a novel reovirus-based vaccine platform and has been completed by finding that a part of the S1 gene of reovirus can be replaced by various exogenous epitope-coding genes whereby the recombinant reovirus thus constructed infects target cells not only to induce the expression of the epitopes, but also to activate immune functions of immune cells against the epitopes, thus enabling effective prevention and treatment of corresponding epitope-related diseases. Using the reovirus-based vaccine platform of the present invention, vaccines carrying various epitopes can be prepared through relatively simple genetic manipulation technology and can be administered in various modes, including oral administration. Thus, the platform can find various applications in the field of preventing and treating various cancers and infectious diseases including SARS-CoV-2 virus infection.

Resumen de: WO2023049300A1

Several known coronaviruses are circulating in animals that have not yet infected humans. An urgent need exists for an effective and safe method of preventing and/or inhibiting CoViD-19, and the symptoms thereof. The present invention provides a method of inhibiting a viral respiratory disease, comprising: administering to a subject, in need thereof, an effective amount of L. reuteri strain 3632 and/or strain 3630, wherein L. reuteri strain 3632 and/or strain 3630 secrete mersacidin. Where the strain is administered by probiotic composition.

Resumen de: WO2023048434A1

The present invention relates to a composition for treating coronavirus disease 2019 (COVID-19) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients. Specifically, since it has been confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who have received a combination of an antiviral agent and a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor, the inflammasome inhibitor containing the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof, and the antiviral agent can be used as active ingredients of a composition for preventing or treating lower respiratory tract infectious diseases including COVID-19.

Resumen de: WO2023047419A1

The invention discloses vaccine for coronavirus and influenza virus and method for preparation thereof. More specifically, the invention discloses seasonal viral vaccine i. e. coronavirus and influenza virus vaccine for prophylaxis of novel coronavirus (SARS-CoV-2) infection (COVID-19) and Influenza virus in mammals and method for preparation of such vaccine. The invention discloses the stable combination vaccine compositions of killed-inactivated SARS-CoV-2, Influenza virus (A and B strains) as antigens. The present invention further discloses method of adaptation and growth seasonal influenza (A and B) strains in cell culture and methods of inactivation and purification of influenza virus bulk antigen. The present invention also discloses SARS-CoV-2 vaccine formulation with inactivated Influenza viruses and use of the same to elicit immune response against the SARS-CoV-2 and Influenza viruses in mammals and humans.

Resumen de: WO2023046039A1

An anti-SARS-CoV-2 E484Q spike protein monoclonal antibody and an application thereof. Provided are an anti-SARS-CoV-2 E484Q spike protein monoclonal antibody, and amino acid sequences of a heavy chain variable region and a light chain variable region thereof. The provided anti-SARS-CoV-2 E484Q spike protein monoclonal antibody can specifically bind to a SARS-CoV-2 E484Q spike protein, and part of the antibody can effectively block the binding of the SARS-CoV-2 E484Q spike protein to an ACE2 protein. The provided anti-SARS-CoV-2 E484Q spike protein monoclonal antibody and the potential medical use provide possibility and convenience for the treatment and detection of SARS-CoV-2 E484Q virus mutant strains containing spike protein E484Q mutation sites.

Resumen de: WO2023044966A1

The use of a compound KYA1797K in the preparation of an anti-RNA virus drug. In particular, the compound has an anti-RNA virus effect, which is mainly due to the fact that the small molecule KYA1797K can inhibit the infection and replication of VSV and SARS-CoV2. The small molecule can be used as a potential clinical trial drug for treating VSV and SARS-CoV2 infection-related diseases, is expected to become a new therapeutic means to prolong the survival period of a patient and improve the survival quality of a patient, and also has an important prompting effect on treating RNA virus-related tumors.

Resumen de: WO2023048334A1

The present invention provides a Lactobacillus plantarum) Probio 88 strain and an extract and a composition, each containing same. The strain, extract, and composition according to the present invention have the effects of suppressing SARS-CoV-2 infection and replication, reducing the intracellular accumulation of inflammation and reactive oxygen species (ROS), decreasing extracellular signal-regulated kinase (ERK) activity, enhancing antiviral activity, and being able to be advantageously used as a therapeutic agent or adjuvant for coronaviral diseases.

Resumen de: WO2023046057A1

Provided are a monoclonal antibody against SARS-CoV-2 spike protein L452R mutant, and amino acid sequences of a heavy chain variable region and light chain variable region thereof. The provided monoclonal antibody against SARS-CoV-2 spike protein L452R mutant can specifically bind to SARS-CoV-2 spike protein L452R mutant, and part of the antibody can effectively block the binding of L452R mutant protein of the SARS-CoV-2 spike protein to ACE2 protein. The provided monoclonal antibody against SARS-CoV-2 spike protein L452R mutant and the potential medical use provide possibility and convenience for the treatment and detection of SARS-CoV-2 virus mutant strains containing L452R mutation sites of the spike protein.

Resumen de: WO2023045076A1

Disclosed in the present invention is a sterilizing robot. The sterilizing robot comprises a movement device, a supporting device and a sterilizing device, wherein the movement device controls the supporting device and the sterilizing device to move; the supporting device comprises a host device, the host device controlling the operation of the movement device and the sterilizing device; and the sterilizing device comprises a gas sterilizing device and a liquid sterilizing device, the gas sterilizing device and the liquid sterilizing device being used for disinfection and sterilization. The sterilizing robot of the present invention has the advantages of a photocatalyst being used for disinfection and sterilization, such that bacteria, germs and viruses floating in the air and attached to aerosol, including H1N1, SARS, influenza virus, coronavirus, etc. can be rapidly killed, and the sterilization rate being up to 99% or more; in addition, 114 toxic pollution gases and odors which are classified in nine types as published by the United States Environmental Protection Agency can all be quickly removed and ultimately degraded into carbon dioxide and water, and the removal rate is up to 99.9% or more on average.

Resumen de: WO2023044542A1

Single and multivalent vaccines against SARS-CoV-2 comprised out of non-structural protein 3 (NSP3), nucleocapsid (N), SI subunit of the Spike protein, the receptor binding domain (RBD) of the Spike protein, or a combination of two or more of them as fusion DNA constructs. Additionally, the vaccines comprise antigens with an oligomerisation domain which can be an IMX313P or Foldon, or additionally encode perforin.

Resumen de: US2023095701A1

Use of albiflorin or a pharmaceutically acceptable salt thereof or an extract or a pharmaceutical composition containing albiflorin in the preparation of a medicament for preventing or treating coronavirus pneumonia, especially novel coronavirus pneumonia, or use thereof in the preparation of a medicament for treating prolonged symptoms of novel coronavirus pneumonia, performing rehabilitation conditioning after recovery of novel coronavirus pneumonia, or alleviating a possible sequela of novel coronavirus pneumonia, the sequela being depression, anxiety, sleep disorder, pain, palpitation, asthma, intestinal function disorder, or chronic fatigue syndrome. Albiflorin has the effects of anti-coronavirus, anti-inflammatory, inflammatory storm inhibition, human microecological balance regulation, etc., can comprehensively prevent and treat coronavirus-induced pneumonia, and can be prepared into medicaments, health care products or nutrition regulators for preventing or treating coronavirus pneumonia, especially novel coronavirus pneumonia.

Resumen de: US2023098743A1

The present invention relates to bacterial strains and compositions thereof for use in the treatment of viral infections of the respiratory tract, preferably from coronavirus, such as for example a severe acute respiratory syndrome coronavirus (COVID-19), by stimulating and/or modulating cytokines and/or markers involved in the inflammatory processes of said viral infections of the respiratory tract.

Resumen de: US2023097374A1

The present invention relates to expression of SARS-CoV like virus proteins [S, M and E] proteins; recombinant polynucleotides, polypeptides; constructs, virus-like particles (VLPs); immunogenic compositions or vaccines comprising Virus Like Particles (VLPs). Method of producing the VLPs/expressing the multi-subunit virus like proteins and method for co-expression of multi-subunit and virus like proteins (VLPs) are also provided. The present invention also provides strategies, methods, systems, kits and combinations for scalable expression, purification and enhanced production of the virus like proteins of SARS-CoV while maintaining their size range and composition. Such multi-subunit VLPs can be utilized to make immunogenic compositions or vaccines.